Cytek Biosciences (CTKB) Competitors $3.71 -0.04 (-1.07%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTKB vs. TXG, TRNS, LAB, EYPT, SENS, ALNT, AEHR, QSI, QTRX, and MASSShould you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Senseonics (SENS), Allient (ALNT), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Cytek Biosciences vs. 10x Genomics Transcat Standard BioTools EyePoint Pharmaceuticals Senseonics Allient Aehr Test Systems Quantum-Si Quanterix 908 Devices Cytek Biosciences (NASDAQ:CTKB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Which has more risk & volatility, CTKB or TXG? Cytek Biosciences has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Does the MarketBeat Community prefer CTKB or TXG? 10x Genomics received 40 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 50.82% of users gave 10x Genomics an outperform vote while only 45.83% of users gave Cytek Biosciences an outperform vote. CompanyUnderperformOutperformCytek BiosciencesOutperform Votes2245.83% Underperform Votes2654.17% 10x GenomicsOutperform Votes6250.82% Underperform Votes6049.18% Which has stronger earnings & valuation, CTKB or TXG? Cytek Biosciences has higher earnings, but lower revenue than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytek Biosciences$200.45M2.37-$12.15M-$0.05-74.2010x Genomics$610.79M1.66-$182.63M-$1.52-5.44 Do analysts rate CTKB or TXG? Cytek Biosciences presently has a consensus target price of $6.42, indicating a potential upside of 72.96%. 10x Genomics has a consensus target price of $18.85, indicating a potential upside of 127.89%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts plainly believe 10x Genomics is more favorable than Cytek Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytek Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.3310x Genomics 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38 Is CTKB or TXG more profitable? Cytek Biosciences has a net margin of -5.05% compared to 10x Genomics' net margin of -29.90%. Cytek Biosciences' return on equity of -2.58% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Cytek Biosciences-5.05% -2.58% -2.05% 10x Genomics -29.90%-25.40%-19.69% Does the media refer more to CTKB or TXG? In the previous week, 10x Genomics had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 8 mentions for 10x Genomics and 6 mentions for Cytek Biosciences. 10x Genomics' average media sentiment score of 1.30 beat Cytek Biosciences' score of 1.00 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of CTKB or TXG? 69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 9.6% of Cytek Biosciences shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Summary10x Genomics beats Cytek Biosciences on 12 of the 18 factors compared between the two stocks. Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTKB vs. The Competition Export to ExcelMetricCytek BiosciencesAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$480.36M$4.16B$5.57B$7.83BDividend YieldN/A0.58%5.11%4.22%P/E Ratio-46.3727.2922.4418.48Price / Sales2.374.23394.09103.59Price / Cash206.1636.1438.1834.62Price / Book1.281.686.774.25Net Income-$12.15M-$83.57M$3.22B$248.23M7 Day Performance-2.88%-3.36%1.49%0.89%1 Month Performance-5.36%0.22%4.00%3.53%1 Year Performance-41.76%-33.36%16.21%5.08% Cytek Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTKBCytek Biosciences2.5796 of 5 stars$3.71-1.1%$6.42+73.0%-38.3%$480.36M$200.45M-46.37500Positive NewsTXG10x Genomics4.6618 of 5 stars$7.68+2.3%$19.79+157.6%-71.8%$939.28M$610.79M-5.051,240News CoverageHigh Trading VolumeTRNSTranscat2.7187 of 5 stars$83.55-1.2%$111.50+33.5%-26.1%$777.77M$272.20M45.16920News CoveragePositive NewsLABStandard BioTools2.8585 of 5 stars$1.19+2.6%$2.50+110.1%-55.2%$450.99M$174.43M-1.68620Upcoming EarningsNews CoverageEYPTEyePoint Pharmaceuticals1.7155 of 5 stars$5.90+3.9%$26.63+351.3%-61.3%$405.50M$43.27M-2.95120Upcoming EarningsNews CoveragePositive NewsSENSSenseonics1.8898 of 5 stars$0.60+0.0%$2.00+233.3%+52.9%$392.53M$22.47M-4.6290News CoverageALNTAllient3.9888 of 5 stars$20.32-3.3%$31.00+52.6%-27.4%$344.38M$529.97M23.091,950Upcoming EarningsShort Interest ↑News CoverageAEHRAehr Test Systems3.6187 of 5 stars$7.96-1.6%$25.00+214.1%-28.8%$236.98M$61.48M10.6190Positive NewsQSIQuantum-Si2.4165 of 5 stars$1.09-5.2%$3.48+218.8%-29.2%$199.62M$3.06M-1.70150News CoverageGap DownQTRXQuanterix2.4618 of 5 stars$4.89-5.0%$18.25+273.2%-64.3%$189.68M$135.44M-4.61460Upcoming EarningsAnalyst ForecastNews CoverageMASS908 Devices1.1601 of 5 stars$4.80+0.8%$5.33+11.1%-4.7%$169.58M$59.63M-2.7160News Coverage Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Standard BioTools Alternatives EyePoint Pharmaceuticals Alternatives Senseonics Alternatives Allient Alternatives Aehr Test Systems Alternatives Quantum-Si Alternatives Quanterix Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTKB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTKB Stock Free CTKB Stock Alerts